Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
    6.
    发明授权
    Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds 失效
    巴比妥酸衍生物,其制备方法和含有这些化合物的药剂

    公开(公告)号:US06472396B1

    公开(公告)日:2002-10-29

    申请号:US09594700

    申请日:2000-06-16

    IPC分类号: C07D23962

    CPC分类号: C07D401/04 C07D239/62

    摘要: Compounds of formula I, useful as matrix metalloprotease inhibitors, wherein X, Y and Z are each oxygen; R1 is selected from the group consisting of (a) n-octyl, (b) n-decyl, (c) biphenyl and (d) (4-phenoxy)phenyl, wherein the terminal monocycle for moieties (c)-(d) is unsubstituted or substituted by a substituent selected from the group consisting of —NH2, —NO2, —SO2NH2, —SO2CH3, acetyl, hydroxy, methoxy, ethoxy, cyano and halogen; R2 and R3 are each hydrogen; and R4 and R5, together with the nitrogen atom to which they are bound, form a piperazinyl or piperidyl ring, wherein the piperazinyl ring is substituted in the 4-position with a substituent selected from the group consisting of (a) a 6-membered aromatic monocycle having 0, 1 or 2 nitrogen atoms and the remainder of the atoms in the monocycle being carbon and (b) hydroxy-C1-C6 alkyl, wherein the monocycle is unsubstituted or substituted by a substituent selected from the group consisting of halogen, —NH2, —NO2, —SO2NH2, —SO2CH3, acetyl and cyano.

    摘要翻译: 可用作基质金属蛋白酶抑制剂的式I化合物,其中X,Y和Z各自为氧; R 1选自(a)正辛基,(b)正癸基,(c)联苯和(d) (4-苯氧基)苯基,其中部分(c) - (d)的末端单环是未取代的或被选自-NH 2,-NO 2,-SO 2 NH 2,-SO 2 CH 3,乙酰基,羟基,甲氧基 ,乙氧基,氰基和卤素; R 2和R 3各自为氢; 和R 4和R 5与它们所连接的氮原子一起形成哌嗪基或哌啶基环,其中哌嗪环在4位被取代基取代,所述取代基选自(a)6元芳族 具有0,1或2个氮原子的单环,并且单环中的其余原子为碳和(b)羟基-C 1 -C 6烷基,其中所述单环是未取代的或被选自以下的取代基取代:卤素, NH 2,-NO 2,-SO 2 NH 2,-SO 2 CH 3,乙酰基和氰基。

    Barbituric acid derivatives, processes for their production and
pharmaceutical agents containing these compounds
    7.
    发明授权
    Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds 失效
    巴比妥酸衍生物,其制备方法和含有这些化合物的药剂

    公开(公告)号:US06110924A

    公开(公告)日:2000-08-29

    申请号:US91352

    申请日:1998-06-18

    CPC分类号: C07D401/04 C07D239/62

    摘要: Compounds of formula I, useful as matrix metalloprotease inhibitors, ##STR1## wherein X, Y and Z are each oxygen;R.sub.1 is selected from the group consisting of (a) n-octyl, (b) n-decyl, (c) biphenyl and (d) (4-phenoxy)phenyl, wherein the terminal monocycle for moieties (c)-(d) is unsubstituted or substituted by a substituent selected from the group consisting of --NH.sub.2, --NO.sub.2, --SO.sub.2 NH.sub.2, --SO.sub.2 CH.sub.3, acetyl, hydroxy, methoxy, ethoxy, cyano and halogen;R.sub.2 and R.sub.3 are each hydrogen; andR.sub.4 and R.sub.5, together with the nitrogen atom to which they are bound, form a piperazinyl or piperidyl ring, wherein the piperazinyl ring is substituted in the 4-position with a substituent selected from the group consisting of (a) a 6-membered aromatic monocycle having 0, 1 or 2 nitrogen atoms and the remainder of the atoms in the monocycle being carbon and (b) hydroxy-C.sub.1 -C.sub.6 alkyl, wherein the monocycle is unsubstituted or substituted by a substituent selected from the group consisting of halogen, --NH.sub.2, --NO.sub.2, --SO.sub.2 NH.sub.2, --SO.sub.2 CH.sub.3, acetyl and cyano.

    摘要翻译: PCT No.PCT / EP96 / 05766 Sec。 371日期:1998年8月26日 102(e)1998年8月26日PCT 1996年12月20日PCT PCT。 公开号WO97 / 23465 PCT 日期1997年7月3日,式I化合物可用作基质金属蛋白酶抑制剂,其中X,Y和Z各自为氧; R 1选自(a)正辛基,(b)正癸基,(c)联苯基和(d)(4-苯氧基)苯基,其中(c) - (d)部分的末端单环, 未取代或被选自-NH 2,-NO 2,-SO 2 NH 2,-SO 2 CH 3,乙酰基,羟基,甲氧基,乙氧基,氰基和卤素的取代基取代。 R2和R3各自为氢; 和R 4和R 5与它们所结合的氮原子一起形成哌嗪基或哌啶基环,其中哌嗪环在4-位被取代基取代,所述取代基选自(a)6-元 具有0,1或2个氮原子的芳族单环,并且单环中的其余原子为碳和(b)羟基-C 1 -C 6烷基,其中所述单环未被取代或被选自以下的取代基取代:卤素, -NH 2,-NO 2,-SO 2 NH 2,-SO 2 CH 3,乙酰基和氰基。